Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer

NCT06931769 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT06931769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06931769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer
Lead sponsor
The Netherlands Cancer Institute
Phase
Observational
Overall status
Recruiting
Start date
November 6, 2025
Completion date
July 1, 2030
Enrollment
100 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer